The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 9:50 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #97. Sagent Pharmaceuticals, Inc. 50% interest of its joint venture partner, Chengdu Kanghong Pharmaceuticals (Group) Co. Ltd. formerly Chengdu Kanghong Technology (Group) Co. Ltd.

Acquirer: Sagent Pharmaceuticals, Inc. (SGNT)
Acquiree: 50% interest of its joint venture partner, Chengdu Kanghong Pharmaceuticals (Group) Co. Ltd. formerly Chengdu Kanghong Technology (Group) Co. Ltd.
Details: Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced an agreement to acquire the 50% interest of its joint venture partner, Chengdu Kanghong Pharmaceuticals (Group) Co. Ltd. formerly Chengdu Kanghong Technology (Group) Co. Ltd. ("Kanghong"), in the Kanghong Sagent (Chengdu) Pharmaceutical Corporation Limited ("KSCP") joint venture, for $25 million, payable in installments through September 2015. Upon completion of the acquisition, KSCP will become a wholly-owned subsidiary of Sagent.

Sagent Pharmaceuticals provides pharmaceuticals to the hospital market, which Co. sells primarily throughout North America. Co. has two segments: Sagent US and Omega. As of Dec 31 2015, Co.'s product portfolio had a total of 55 products in its Sagent US segment and 48 products in its Omega segment. Co.'s product categories include: anti-infective products, which assist in the treatment of various infections and related symptoms; oncology products, which are used in the treatment of cancer and cancer-related medical problems; and critical care products, which are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives.

Open the SGNT Page at The Online Investor »

Company Name: 
Sagent Pharmaceuticals Inc
Website: 
www.sagentpharma.com
Sector: 
Drugs & Pharmaceuticals
 

Open the SGNT Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree SGNT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 97 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.